Zhao Xiangshan, Goswami Monica, Pokhriyal Nidhi, Ma Hui, Du Hongyan, Yao Jun, Victor Thomas A, Polyak Kornelia, Sturgis Charles D, Band Hamid, Band Vimla
Division of Cancer Biology, Department of Medicine, Evanston Northwestern Healthcare Research Institute and Feinberg School of Medicine, Evanston, IL, USA.
Cancer Res. 2008 Jan 15;68(2):467-75. doi: 10.1158/0008-5472.CAN-07-0782.
Identification of molecular aberrations in premalignant human mammary epithelial cells (hMEC), the precursors for breast cancers, is a central goal in breast cancer biology. Recent studies implicated expression of cyclooxygenase 2 (COX-2) as a marker to identify precursor cells for breast cancer. In this study, we analyzed COX-2 expression in preselection and postselection hMEC cells and observed similar COX-2 levels in both cells. Interestingly, immortalization of postselection cells using various methods leads to a dramatic decrease in COX-2 expression. Similar to immortal cells, the majority of breast cancer cell lines expressed low levels of COX-2 protein. Finally, analyses of COX-2 expression in a series of specimens from reduction mammoplasty, adenosis, ductal carcinoma in situ, and infiltrating ductal carcinoma showed down-regulation of COX-2 expression during tumor progression. Importantly, down-regulation of COX-2 using small interfering RNA in cells showed no effect on cell proliferation, anchorage-independent growth, migration, or invasion. These results show that (a) COX-2 overexpression does not seem to predict a breast cancer precursor cell and does not provide advantage for the cell to be transformed; (b) inhibition of COX-2 does not affect hMEC growth and oncogenic behavior in the conditions analyzed; and (c) COX-2 expression is decreased in breast cancer cell lines and cancer specimens as compared with normal mammary epithelial cells.
鉴定癌前人类乳腺上皮细胞(hMEC)中的分子畸变是乳腺癌生物学的核心目标,而hMEC是乳腺癌的前体细胞。最近的研究表明,环氧合酶2(COX-2)的表达可作为鉴定乳腺癌前体细胞的标志物。在本研究中,我们分析了预选和筛选后hMEC细胞中COX-2的表达情况,发现两种细胞中的COX-2水平相似。有趣的是,使用各种方法对筛选后细胞进行永生化处理会导致COX-2表达显著降低。与永生化细胞类似,大多数乳腺癌细胞系表达的COX-2蛋白水平较低。最后,对一系列来自缩乳术、腺病、导管原位癌和浸润性导管癌标本的COX-2表达分析表明,在肿瘤进展过程中COX-2表达下调。重要的是,在细胞中使用小干扰RNA下调COX-2对细胞增殖、非锚定依赖性生长、迁移或侵袭没有影响。这些结果表明:(a)COX-2过表达似乎不能预测乳腺癌前体细胞,也不能为细胞转化提供优势;(b)在分析的条件下,抑制COX-2不影响hMEC的生长和致癌行为;(c)与正常乳腺上皮细胞相比,乳腺癌细胞系和癌组织标本中COX-2表达降低。